Slc50a1, a member of the SLC family, is a novel sugar transporter and membrane protein. As part of the SLC50 family, which in humans has only one member, it may be involved in glucose transmembrane transport [3,5].

In hepatocellular carcinoma (HCC), Slc50a1 is significantly upregulated, correlating with unfavorable prognosis. It can regulate cellular glycolysis and the cell cycle, promoting HCC cell proliferation and reducing apoptosis, while enhancing resistance to drugs like doxorubicin (DOX) and 2-DG. The m6A methyltransferase METTL3 mediates its methylation modification, and IGF2BP2 promotes its stability and translational expression [1].

In early breast cancer, Slc50a1 serum levels are higher compared to those with benign breast disease and healthy controls, and its upregulation may be associated with unfavorable prognosis, suggesting it could be a potential diagnostic biomarker [2]. Bioinformatics analysis also confirmed its diagnostic value in breast cancer, and its protein expression was associated with estrogen receptor and HER2 status, while high-grade breast cancer patients with high Slc50a1 levels had unfavorable 3-year outcomes, indicating its potential as an independent prognostic factor [3].

Genome-wide association studies found that a locus near Slc50a1 is associated with 1,5-anhydroglucitol concentrations, suggesting a role in glucose metabolism [4].

Whole-exome sequencing in Chinese early-onset Parkinson's disease (EOPD) patients identified rare variants in Slc50a1, though the significance of these variants is yet to be fully understood [6].

In Pakistani families with non-syndromic intellectual disability, a novel homozygous variant in Slc50a1 was found, suggesting its potential role in cognitive impairment [7].

In cutaneous T-cell lymphomas, an alternative splicing event related to Slc50a1 was identified in association with histone deacetylase inhibitor resistance or sensitivity [8].

In summary, Slc50a1 is involved in multiple biological processes and diseases. Its role in glucose-related metabolism and as a potential biomarker in cancers, along with its possible connections to neurodegenerative and cognitive disorders, highlights its importance. Research on Slc50a1 using various genetic models could further clarify its functions and provide insights into disease mechanisms and potential therapeutic targets.